Morning light biological to donate more than 300 million yuan of materials to help Hubei epidemic front line

the outbreak of New Coronavirus pneumonia has been affecting the hearts of Hebei-based Chenguang Biotech Group (hereinafter referred to as Chenguang Bio) Following the donation of the first batch of 2000 bottles of lycopene softgels to five hospitals in Wuhan, Hubei Province, on the afternoon of March 6, the second batch of materials donated by Morninglight Bio arrived in Wuhan again. This time, Chenguang Bio donated 19,000 bottles of lycopene softgels worth more than 3.2 million yuan to Wuhan Hospital (also known as Hubei Provincial People's Hospital) and Jianghan University Hospital in Wuhan, a designated hospital for patients with new coronavirus pneumonia. (Morning light biological second batch of donated materials arrived at Wuhan University People's Hospital) (MorningLight Bio second batch of donated materials arrived in Wuhan Jianghan University Hospital) "This batch of lycopene softgels was made in an emergency Lycopene has the function of removing free radicals and enhancing immunity, hoping to make some contributions to front-line health care workers and do their part to protect their health Lu Qingguo, chairman of MorningLight Bio, said, "In the face of the severe outbreak, front-line health care workers rushed to the front line, they are the most respectable and lovely people, but also the most worthy of love." (Lu Qingguo and staff packed donated materials together) "After contacting the donated hospital and learning of the exact number of first-line medical staff, we plan to prepare the donation amount for two months per person At this time found that the spot quantity is far short of supply, but raw materials are enough, if the resumption of production is still short of package materials, we quickly contact the supplier of package materials, emergency coordination of the supply of package materials The chairman asked us to overcome all difficulties to resume production, the production of front-line workers overtime to catch up with lycopene softgels, hoping that the first time the product to the first line of medical staff hands "Morning Light Bio co., Ltd manager Wan Haichao said. When the outbreak of new coronavirus pneumonia broke out just before the Spring Festival, Lu Qingguo was also studying in Africa After learning of the severe situation of the epidemic, he urgently deployed domestic and foreign resources, the deployment of the group and branch of the donation work. It is reported that morning light biological through the city and Quzhou County Red Cross to the local organs of schools, hospitals and health hospitals donated 41162 liters 75% alcohol disinfection liquid, 15,000 N99 and KN95 masks and 10,000 disposable masks, 125 sets of protective clothing, 24 goggles Subsidiaries in Xinjiang, Yunnan and other places also donated 3,500 KN95 masks, 4,500 disposable masks and 100 protective clothing Up to now, the morning light biological anti-epidemic donation materials accumulated more than 4.2 million yuan. Morning Light Bio is a GEM-listed company focused on plant extraction and leading the world's natural pigment industry, and is also an important international supplier of natural plant extracts Its core products include natural colors, natural fragrance extracts and essential oils, natural nutrition and medicinal extracts, plant protein and oil four categories of more than 80 varieties, of which natural pigment production and sales in the forefront of the country, single-product capsaicin, capsaicin resin, lutein production and sales are ranked in the forefront of the world. At present, Morninglight Bio is the world's second largest producer of lycopene, with the leading domestic technological achievements of lycopene and 4 national technology invention patents, among which, "tomato processing industrialization key technological innovation and application" won the second prize of national scientific and technological progress In 2019, the export value of the morning light biolyscarine products reached more than 3 million US dollars. Morninglight Bio's 2019 annual results report showed that total operating income was RMB3.267 billion, up 6.63% YoY, total profit was RMB210 million, up 38.99% YoY, and net profit attributable to shareholders of listed companies was RMB193 million, up 33.14% YoY 0
1
0
1